Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.

by Leandro Cerchietti, Christine Damm-Welk, Inga Vater, Wolfram Klapper, Lana Harder, Christiane Pott, Shao Ning Yang, Alfred Reiter, Reiner Siebert, Ari Melnick, Willi Woessmann
Published 2011-01-01

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma

by Vijay Kumar Singh, Sebastian Werner, Simone Schwalm, Volker Lennerz, Stephanie Ruf, Serena Stadler, Holger Hackstein, Alfred Reiter, Thomas Wölfel, Christine Damm-Welk, Wilhelm Woessmann
Published 2019-09-01

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

by Lara Mussolin, Marié-Cecilé Le Deley, Elisa Carraro, Christine Damm-Welk, Andishe Attarbaschi, Denise Williams, Amos Burke, Keizo Horibe, Atsuko Nakazawa, Grazyna Wrobel, Georg Mann, Monika Csóka, Anne Uyttebroeck, Rafael Fernández-Delgado Fernández-Delgado Cerdá, Auke Beishuizen, Karin Mellgren, Birgit Burkhardt, Wolfram Klapper, Suzanne D. Turner, Emanuele S.G. D’Amore, Laurence Lamant, Alfred Reiter, Wilhelm Woessmann, Laurence Brugières, Marta Pillon on behalf of the European Inter-Group for Childhood Non-Hodgkin lymphoma Pillon
Published 2020-09-01